A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma
-
Add time:08/24/2019 Source:sciencedirect.com
SummaryBackgroundThis phase 1, dose-finding study determined the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), antitumor activity, and molecular correlates of IPI-926, a Hedgehog pathway (HhP) inhibitor, combined with cetuximab in patients with relapsed/metastatic squamous cell carcinoma of the head and neck.
We also recommend Trading Suppliers and Manufacturers of CI 926 (cas 104683-52-5). Pls Click Website Link as below: cas 104683-52-5 suppliers
Prev:Chapter Ten - Atomic Electronic Structure Computations With Hylleraas-CI Wave Functions
Next:ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Clinical InvestigationValvular and Congenital Heart DiseaseRetrospective cohort analysis of 926 tricuspid valve surgeries: Clinical and hemodynamic outcomes with propensity score analysis08/27/2019
- The low-lying singlet electronic excited states of HfO2: A symmetry adapted cluster–configuration interaction (SAC-CI) study08/26/2019
- ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells08/25/2019
- Chapter Ten - Atomic Electronic Structure Computations With Hylleraas-CI Wave Functions08/23/2019
- ArticleAntagonism of scopolamine-induced memory impairments in rats by the muscarinic agonist RU 35 926 (CI-979)08/22/2019
